- Home
- SORA vs SCYX Comparison
SORA vs SCYX Comparison
Compare SORA & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SORA | SCYX |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | Hong Kong | United States |
| Employees | 7 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 41.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SORA | SCYX |
|---|---|---|
| Price | $2.09 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 7.6K | ★ 427.0K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $0.57 |
| 52 Week High | $10.27 | $1.29 |
Technical Indicators
Market Signals| Indicator | SORA | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 65.62 |
| Support Level | $1.76 | $0.65 |
| Resistance Level | $2.15 | $1.29 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 46.65 | 97.94 |
Price Performance
Historical ComparisonAbout SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.